Providence Health & Services

This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) to control metastatic HER2-negative breast cancer without using chemotherapy. The goal is to see if this approach can shrink tumors or keep them stable for at least 24 weeks. The trial involve…

This early-phase study tests a new combination of two treatments—cabozantinib (a targeted drug) and radioactive Lu-177 DOTATATE—for people with advanced neuroendocrine tumors that have stopped responding to standard therapy. The main goal is to find the safest dose of cabozantini…

This early-phase trial tests a new approach for people with incurable epithelial cancers. Patients receive specially engineered immune cells (TCR-T) that target unique markers on their tumors, plus two drugs that boost the immune response. The main goal is to check safety and fin…

This study tests whether giving a short course of immunotherapy (pembrolizumab) plus targeted radiation before surgery can shrink advanced head and neck cancers. The trial includes 28 adults with stage III or IVA HPV-negative head and neck squamous cell carcinoma. The main goal i…

This early-phase study tests the safety of combining a cancer vaccine (DPX-Survivac) with hormone therapy, and sometimes radiation or chemotherapy, before surgery in people with HR+HER2- breast cancer. The goal is to see if these combinations are safe and do not delay planned sur…

This study tests a new drug, MK-3475, added to standard chemotherapy (gemcitabine) in people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to find the safest dose and see if the combination helps control the cancer. Sixteen particip…

This study tests a new treatment for people with advanced cancers that have a specific genetic change called KRAS G12V. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. Participants must also have a specific…

This study tests whether adding extra immunotherapy before standard treatment can help the immune system better attack triple negative breast cancer. About 12 adults with untreated, locally confirmed TNBC will receive different immunotherapy combinations plus chemotherapy before …

This early-stage trial tests a personalized treatment for people with incurable epithelial cancers. Doctors take a patient's own immune cells, engineer them to recognize unique markers on their tumor, and infuse them back along with drugs that boost the immune response. The goal …

This study tests whether adding the experimental drug LY2157299 to standard chemotherapy and radiation can improve outcomes for people with locally advanced rectal cancer. About 50 adults will receive the combination over 8 weeks, and researchers will track tumor response and imm…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and effective for people with metastatic triple negative breast cancer. About 29 adults with advanced disease that cannot be removed by surgery will receive one of two chemothera…

This study compares two treatments for metastatic melanoma that has spread: high-dose immunotherapy (IL-2) alone versus the same immunotherapy plus targeted radiation (SBRT). The goal is to see if adding radiation helps shrink tumors better. 44 adults with up to 3 tumors that can…

This study tests whether a two-drug targeted therapy (encorafenib and binimetinib) works better with or without the immunotherapy drug nivolumab for people with a specific type of advanced thyroid cancer (BRAF V600 mutant) that has spread and no longer responds to standard radioa…

This study looks at whether a device called Amma can help women with early-stage breast cancer keep more of their hair during chemotherapy. About 15 women will use the device and report how satisfied they are. The goal is to see if offering this option in cancer centers is practi…

This early-stage study looks at whether injecting the drug ipilimumab directly into head and neck tumors before surgery is safe and practical. About 18 adults with squamous cell carcinoma of the head and neck will receive the injection, then have their tumor removed as planned. R…